Literature DB >> 2729754

Pathologic and immunologic alterations in early stages of beryllium disease. Re-examination of disease definition and natural history.

L S Newman1, K Kreiss, T E King, S Seay, P A Campbell.   

Abstract

Beryllium lung disease is a chronic granulomatous disorder in which a beryllium-specific immune response plays a central role. By using a measure of cellular immune response to beryllium salts, bronchoalveolar lavage (BAL), and lung biopsy, we have identified 12 new cases of beryllium disease. Each of these individuals had pathologic changes on biopsy, lymphocytic alveolitis on BAL, and positive BAL lymphocyte transformation tests (LTT) in response to beryllium sulfate. This group of patients was remarkable for its paucity of clinical findings. At initial evaluation, seven had no respiratory symptoms, and four had normal physical examinations. Five had no increase in interstitial markings on chest radiograph. In eight cases, flow rates and lung volumes were normal. Diffusing capacity for carbon monoxide was low in only one case, and oxygen exchange during exercise was normal in six of nine subjects studied. In addition to the 12 cases, we evaluated eight beryllium-exposed workers who had other (nonberyllium) lung diseases; two of these eight demonstrated beryllium sensitization based on BAL LTT. We conclude that use of fiberoptic bronchoscopy with transbronchial biopsy and BAL facilitates diagnosis of beryllium workers who have histopathologic and immunologic alterations consistent with chronic beryllium disease. These findings may precede frank clinical illness and physiologic impairment, having important implications for our understanding of the natural history of beryllium disease.

Entities:  

Mesh:

Year:  1989        PMID: 2729754     DOI: 10.1164/ajrccm/139.6.1479

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  45 in total

1.  SELDI-TOF derived serum biomarkers failed to differentiate between patients with beryllium sensitisation and patients with chronic beryllium disease.

Authors:  B C Tooker; R P Bowler; J M Orcutt; L A Maier; H M Christensen; L S Newman
Journal:  Occup Environ Med       Date:  2011-01-27       Impact factor: 4.402

Review 2.  Clinical application of beryllium lymphocyte proliferation testing.

Authors:  Barbara P Barna; Daniel A Culver; Belinda Yen-Lieberman; Raed A Dweik; Mary Jane Thomassen
Journal:  Clin Diagn Lab Immunol       Date:  2003-11

3.  Risks of beryllium disease related to work processes at a metal, alloy, and oxide production plant.

Authors:  K Kreiss; M M Mroz; B Zhen; H Wiedemann; B Barna
Journal:  Occup Environ Med       Date:  1997-08       Impact factor: 4.402

4.  Frequency of beryllium-specific, central memory CD4+ T cells in blood determines proliferative response.

Authors:  Andrew P Fontenot; Brent E Palmer; Andrew K Sullivan; Fenneke G Joslin; Cara C Wilson; Lisa A Maier; Lee S Newman; Brian L Kotzin
Journal:  J Clin Invest       Date:  2005-09-08       Impact factor: 14.808

5.  Up-regulation of programmed death-1 expression on beryllium-specific CD4+ T cells in chronic beryllium disease.

Authors:  Brent E Palmer; Douglas G Mack; Allison K Martin; May Gillespie; Margaret M Mroz; Lisa A Maier; Andrew P Fontenot
Journal:  J Immunol       Date:  2008-02-15       Impact factor: 5.422

6.  5-Aminosalicylic Acid Modulates the Immune Response in Chronic Beryllium Disease Subjects.

Authors:  Brian J Day; Jie Huang; Briana Q Barkes; May Gillespie; Li Li; Lisa A Maier
Journal:  Lung       Date:  2017-10-27       Impact factor: 2.584

7.  Deficient and dysfunctional regulatory T cells in the lungs of chronic beryllium disease subjects.

Authors:  Douglas G Mack; Allison M Lanham; Michael T Falta; Brent E Palmer; Lisa A Maier; Andrew P Fontenot
Journal:  Am J Respir Crit Care Med       Date:  2010-03-18       Impact factor: 21.405

8.  Screening for chronic beryllium disease using beryllium specific lymphocyte proliferation testing.

Authors:  T N Markham
Journal:  Int Arch Occup Environ Health       Date:  1996       Impact factor: 3.015

9.  Function associated transforming growth factor-beta gene polymorphism in chronic beryllium disease.

Authors:  Karoline I Gaede; Massimo Amicosante; Manfred Schürmann; Elisabeth Fireman; Cesare Saltini; Joachim Müller-Quernheim
Journal:  J Mol Med (Berl)       Date:  2005-03-05       Impact factor: 4.599

10.  Sulfasalazine and mesalamine modulate beryllium-specific lymphocyte proliferation and inflammatory cytokine production.

Authors:  Dave R Dobis; Richard T Sawyer; May M Gillespie; Lee S Newman; Lisa A Maier; Brian J Day
Journal:  Am J Respir Cell Mol Biol       Date:  2009-11-09       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.